Trametinib + Anlotinib + Tislelizumab
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
KRAS Mutation-Related Tumors
Conditions
KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor
Trial Timeline
Jul 1, 2024 → Dec 31, 2028
NCT ID
NCT06456138About Trametinib + Anlotinib + Tislelizumab
Trametinib + Anlotinib + Tislelizumab is a phase 1/2 stage product being developed by Novartis for KRAS Mutation-Related Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06456138. Target conditions include KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06456138 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in KRAS Mutation-Related Tumors